Physician profile
Patrick M Hayes
NPI 1477745636
$439.88
in general payments reported to CMS, 2019-2025
12 companies · $38.71 in 2025
The $38.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2021: $23.32 · 2024: $23.45 · 2025: $38.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $109.97 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $79.86 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.50 | 2019 | |
| Amgen INC. | $29.04 | 2019 | |
| Lilly USA, LLC | $26.78 | 2019 | |
| Axsome Therapeutics, INC. | $23.45 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $21.96 | 2019 | |
| Abbvie INC. | $17.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.03 | 2019 | |
| Sanofi Pasteur INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.